Nektar Therapeutics Overview
Get informed when a big investor buys or sells
+ Follow237.96
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
Nektar Therapeutics (0UNL.L) currently reports a PEG ratio of 237.96. That is above the Healthcare sector average of 27.75. Use the charts on this page to explore Nektar Therapeutics's PEG ratio history and peer comparisons.
Nektar Therapeutics's PEG ratio of 237.96 is higher than the Healthcare sector average of 27.75. That is roughly 757.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The PEG ratio is a valuation multiple that relates Nektar Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At 237.96, 0UNL.L can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current PEG ratio of 237.96, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 27.75. From there, open related valuation or income-statement pages for Nektar Therapeutics, and consider following 0UNL.L for alerts when major investors trade the stock.
Nektar Therapeutics is classified in the Healthcare sector. On PEG ratio, it currently shows 237.96 versus a sector average near 27.75. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 0UNL.L with unrelated industries.
